Itolizumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组 抗 CD6 单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions.

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD).Animal Model:Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)Dosage:60 μg or 300μg Administration:Intraperitoneal injection (i.p.), prior to PBMC transplantation. Result:Decreased mortality compared to the vehicle (100% vs. 10%).

——

Others

Other Targets

Others

——

——

1116433-11-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years